Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S, et al. Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023;73:620–52. https://doi.org/10.3322/caac.21785.

Article  PubMed  Google Scholar 

Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. N Engl J Med. 2024;391:1313–27. https://doi.org/10.1056/NEJMoa2404873.

Article  PubMed  Google Scholar 

Liang J, Guan X, Bao G, Yao Y, Zhong X. Molecular subtyping of small cell lung cancer. Semin Cancer Biol. 2022;86:450–62. https://doi.org/10.1016/j.semcancer.2022.05.010.

Article  PubMed  Google Scholar 

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220–9. https://doi.org/10.1056/NEJMoa1809064.

Article  PubMed  Google Scholar 

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929–39. https://doi.org/10.1016/s0140-6736(19)32222-6.

Article  PubMed  Google Scholar 

Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22:51–65. https://doi.org/10.1016/s1470-2045(20)30539-8.

Article  PubMed  Google Scholar 

Liu V. Stephen, et al. Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: Imbrella a extension study results. 2023 WCLC; OA01.04.

Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:739–47. https://doi.org/10.1016/s1470-2045(22)00224-8.

Article  PubMed  Google Scholar 

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020;38:2369–79. https://doi.org/10.1200/jco.20.00793.

Article  PubMed  PubMed Central  Google Scholar 

Spigel DR, Vicente D, Ciuleanu TE, Gettinger S, Peters S, Horn L, et al. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331(☆). Ann Oncol. 2021;32:631–41. https://doi.org/10.1016/j.annonc.2021.01.071.

Article  PubMed  Google Scholar 

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. J Clin Oncol. 2021;39:1349–59. https://doi.org/10.1200/jco.20.02212.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Ying, et al. ASTRUM-005: Updated results of first-line serplulimab versus placebo combinated with chemotherapy in extensive-stage small-cell lung cancer. 2022 ESMO ASIA. LBA9.

Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024;19:1073–85. https://doi.org/10.1016/j.jtho.2024.03.008.

Article  PubMed  Google Scholar 

Tu J, Liang H, Li C, Huang Y, Wang Z, Chen X, Yuan X. The application and research progress of anti-angiogenesis therapy in tumor immunotherapy. Front Immunol. 2023;14:1198972. https://doi.org/10.3389/fimmu.2023.1198972.

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024. https://doi.org/10.1038/s41591-024-03132-1.

Article  PubMed  PubMed Central  Google Scholar 

Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, et al. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. N Engl J Med. 2023;389:2063–75. https://doi.org/10.1056/NEJMoa2307980.

Article  PubMed  Google Scholar 

Carlisle JW, Leal T. Advancing immunotherapy in small cell lung cancer. Cancer. 2023;129:3525–34. https://doi.org/10.1002/cncr.34977.

Article  PubMed  Google Scholar 

Burr ML, Sparbier CE, Chan KL, Chan YC, Kersbergen A, Lam EYN, et al. An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell. 2019;36:385-401.e8. https://doi.org/10.1016/j.ccell.2019.08.008.

Article  PubMed  PubMed Central  Google Scholar 

Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, et al. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021;11:1952–69. https://doi.org/10.1158/2159-8290.Cd-20-0913.

Article  PubMed  PubMed Central  Google Scholar 

He Y, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, Yu H, et al. MHC class II expression in lung cancer. Lung Cancer. 2017;112:75–80. https://doi.org/10.1016/j.lungcan.2017.07.030.

Article  PubMed  Google Scholar 

Hamilton G, Rath B. Immunotherapy for small cell lung cancer: mechanisms of resistance. Expert Opin Biol Ther. 2019;19:423–32. https://doi.org/10.1080/14712598.2019.1592155.

Article  PubMed  Google Scholar 

Wang W, Hodkinson P, McLaren F, MacKinnon A, Wallace W, Howie S, Sethi T. Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrate. Int J Cancer. 2012;131:E928–37. https://doi.org/10.1002/ijc.27613.

Article  PubMed  Google Scholar 

Tian T, Gu X, Zhang B, Liu Y, Yuan C, Shao L, et al. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer. Cancer Biomark. 2015;15:425–32. https://doi.org/10.3233/cbm-150473.

Article  PubMed  Google Scholar 

Li T, Qiao T. Unraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy. Semin Cancer Biol. 2022;86:117–25. https://doi.org/10.1016/j.semcancer.2022.09.005.

Article  PubMed  Google Scholar 

Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019;12:67. https://doi.org/10.1186/s13045-019-0753-2.

Article  PubMed  PubMed Central  Google Scholar 

Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17:883–95. https://doi.org/10.1016/s1470-2045(16)30098-5.

Article  PubMed  Google Scholar 

Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017;35:3823–9. https://doi.org/10.1200/jco.2017.72.5069.

Article  PubMed  Google Scholar 

Hellmann MD, Callahan MK, Awad MM, Calvo E, Ascierto PA, Atmaca A, et al. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018;33:853-61.e4. https://doi.org/10.1016/j.ccell.2018.04.001.

Article  PubMed  PubMed Central  Google Scholar 

Chung HC, Lopez-Martin JA, Kao CH, Miller WH, & Piha-Paul, SA.Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158.J Clin Oncol. 2018;36:8506.

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, et al. Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. J Thorac Oncol. 2020;15:618–27. https://doi.org/10.1016/j.jtho.2019.12.109.

Article  PubMed  Google Scholar 

Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, et al. Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2024;30:824–35. https://doi.org/10.1158/1078-0432.Ccr-23-1689.

Article  PubMed  Google Scholar 

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–65. https://doi.org/10.1016/s1470-2045(20)30445-9.